stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) EPS (diluted)
Xenon Pharmaceuticals Inc.'s EPS (diluted) for fiscal 2025 was −$4.36, compared with −$3.01 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.74. Over the past ten years it has ranged from −$4.36 (fiscal 2025) to −$0.81 (fiscal 2020) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 5 consecutive fiscal years. Xenon Pharmaceuticals Inc. ranks 437th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$4.36 | — |
| FY2024 | −$3.01 | — |
| FY2023 | −$2.73 | — |
| FY2022 | −$2.06 | — |
| FY2021 | −$1.77 | — |
| FY2020 | −$0.81 | — |
| FY2019 | −$1.54 | — |
| FY2018 | −$1.63 | — |
| FY2017 | −$1.72 | — |
| FY2016 | −$1.48 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.11 | — |
| Mar 2026 | −$1.17 | — |
| Dec 2025 | −$1.31 | — |
| Sep 2025 | −$1.15 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| XENE Xenon Pharmaceuticals Inc. | −$4.74 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| IRON Disc Medicine, Inc. compare | −$6.58 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on XENE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement